Nitinotes Achieves Major Milestone by Launching EndoZip™ in Spain

Nitinotes’ Groundbreaking EndoZip™ Procedures in Spain

Nitinotes Ltd., a leader in medical technology, has heralded a new chapter in bariatric endoscopy with the completion of its first commercial EndoZip™ procedures in Spain on April 23, 2026. This milestone marks an important extension of the company's European operations after receiving the coveted CE Mark approval.

The pioneering procedures took place at the Madrid Sanchinarro University Hospital, under the expert guidance of Professor Gontrand Lopez-Nava, a highly regarded authority in bariatric endoscopy. His previous work with EndoZip™ during clinical trials was instrumental in gaining the CE Mark, and he continues to utilize the system as part of routine clinical practice. This transition showcases Nitinotes' commitment to advancing minimally invasive techniques in obesity care.

EndoZip™ is engineered to be a fully automated suturing system specifically for endoscopic sleeve gastroplasty (ESG). One of its key advantages is that it allows a single operator to carry out crucial suturing steps with ease. This automation not only enhances procedural accuracy but also ensures that physicians can maintain endoscopic visualization and tactile feedback during procedures.

Prof. Lopez-Nava expressed his enthusiasm about employing EndoZip™ in a commercial setting: "Having worked with EndoZip™ from its early clinical experience, it is encouraging to now use the system in routine practice. Automation has the potential to simplify the ESG workflow while maintaining procedural control. This may lead to greater clinical adoption and improved access to minimally invasive metabolic interventions."

As gastric sleeve procedures continue to rise in popularity as a non-invasive method for substantial weight loss, EndoZip™ serves as a pivotal solution for patients seeking alternatives to traditional surgical options. The initial commercial applications in Spain are indicative of a surging interest in EndoZip™ across Europe, a testament to the system's ability to integrate seamlessly into established surgical practices.

Lloyd Diamond, the Chief Executive Officer of Nitinotes, commented on this significant development: "Expanding into Spain represents an important step in our measured European rollout. We are pleased to collaborate with Prof. Lopez-Nava, whose early clinical experience with EndoZip™ and continued leadership in bariatric endoscopy support the integration of automated ESG into routine practice."

Nitinotes specializes in developing cutting-edge automated endoluminal suturing solutions to address obesity care. While EndoZip™ is currently CE-marked and commercially available in Europe, it is still under investigational status in the United States due to federal regulations.

For further information on Nitinotes and its innovative technology, visit nitinotesurgical.com.

Conclusion

The completion of these procedures in Spain is a promising indication of Nitinotes’ growth in Europe. As EndoZip™ proves itself in clinical settings, it may pave the way for a broader acceptance of automated solutions in the ever-evolving landscape of bariatric surgery. Expect to see more from Nitinotes as they continue to lead the charge in revolutionizing obesity treatment with technology-driven approaches.